A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

MLA

Gotlib, Jason, et al. “A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera.” Blood, vol. 134, no. 1, Number 1 Supplement 1, Nov. 2019, p. 4168. EBSCOhost, https://doi.org/10.1182/blood-2019-123546.

APA

Gotlib, J., Gabrail, N., O’Connell, C. L., Garcia-Delgado, R., Sbardellati, T., Rothbaum, W. M., McGreivy, J., Harrison, C. N., & Kiladjian, J.-J. (2019). A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera. Blood, 134(1, Number 1 Supplement 1), 4168. https://doi.org/10.1182/blood-2019-123546

Chicago

Gotlib, Jason, Nashat Gabrail, Casey L. O’Connell, Regina Garcia-Delgado, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, and Jean-Jacques Kiladjian. 2019. “A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera.” Blood 134 (1, Number 1 Supplement 1): 4168. doi:10.1182/blood-2019-123546.